PIK3CA and breast cancer: The incidence of PIK3CA mutations has been estimated at 36%‐45% of HR+, HER2‐negative breast cancers; up to 40% of HER2‐positive breast cancers; and 9%‐14% of triple‐negative breast cancers.12, 14, 15